Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers

Alcoholism: Clinical and Experimental Research

Volumn 28, Issue 9, 2004, Pages 1362-1370

  Drobes, David J ^a,b   Anton, Raymond F ^a   Thomas, Suzanne E ^a   Voronin, Konstantin ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Alcohol; Craving; Nalmefene; Naltrexone; Stimulation

Indexed keywords

NALMEFENE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO;

ADULT; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; EXPERIMENTAL DESIGN; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEDATION; STIMULATION; WITHDRAWAL SYNDROME;

ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; ANALYSIS OF VARIANCE; BEHAVIOR, ADDICTIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE;

EID: 4544346571     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ALC.0000139704.88862.01     Document Type: Article

References (50)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington, DC.
2. Andreasen NC, Endicott J, Spitzer RL, Winokur G (1977) The family history method using diagnostic criteria. Arch Gen Psychiatry 34:1229-1235.
3. Anton RF, Moak DH, Latham P (1995) The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19:92-99.
4. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of out-patient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156:1758-1764.
5. Anton RF, Swift RM (2003) Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict 12:S53-S68.
6. Beck AT (1967). Depression: Clinical, Experimental, and Theoretical Aspects. Hoeber, New York.
7. Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893-897.
8. Benjamin D, Grant ER, Pohorecky LA (1993) Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 621:137-140.
9. Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ (1995) Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci 56:1187-1192.
10. Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23:195-203.
11. Davidson D, Swift R, Fitz E (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20:732-739.
12. Davis LJ, Hurt RD, Morse RM, O'Brien PC (1987) Discriminant analysis of the Self-Administered Alcoholism Screening Test. Alcohol Clin Exp Res 11:269-273.
13. De Haven-Hudkins DL, Brostrom PA, Alien JT, Lesko LJ, Ferkany JW, Kaplita PV, Manvunkel BJ, Rzeszotarski WJ, Steranka LR (1990) Pharmacologic profile of NPC168 (naltrexonephenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 37:497-504.
14. de Wit H, Svenson J, York A (1999) Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharmacology 146:33-41.
15. Drobes DJ, Anton RF (2000) Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol 61:220-224.
16. Drobes DJ, Anton RF, Thomas SE, Voronin K (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 28:755-764.
17. Emmerson PJ, Liu M, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637.
18. First MB, Spitzer RL, Gibbon M, Williams JBW (1994). Structured Clinical Interview for Axis IDSM-IV Disorders - Patient Edition (SCID-I/P, version 2.0). Biometrics Research Department, New York State Psychiatric Institute.
19. Frezza M, Di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS (1990) High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322:95-99.
20. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, Weterling T, Kielstein V, Labriola D, Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results of a German multicenter study. J Clin Psychopharmacol 22:592-598.
21. Goldman MA (2002) Expectancy and risk for alcoholism: the unfortunate exploitation of a fundamental characteristic of neurobehavioral adaptation. Alcohol Clin Exp Res 26:737-746.
22. Kiefer F, Jahn H, Tarnaske T, Helwig H, Eriken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, Wiedemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry 60:92-99.
23. King AC, Volpicelli JR, Frazer A, O'Brien CP (1997a) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129:15-22.
24. King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ (1997b) Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 21:906-909.
25. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734-1739.
26. Lieber CS, Gentry RT, Baraona E (1994). First pass metabolism of ethanol. Alcohol Alcohol (Suppl) 2:163-169.
27. Martin CS, Earlywine M, Musty RE, Perrine MW, Swift RM (1993) Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res 17:140-146.
28. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence. Alcohol Clin Exp Res 18:1162-1167.
29. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56:719-724.
30. McCaul ME, Wand GS, Rohde C, Lee SM (2000) Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res 24:1385-1391.
31. Middaugh LD, Read E, Boggan WO (1978) Effects of naloxone on ethanol induced alterations of locomotor activity in C57BL/6 mice. Pharmacol Biochem Behav 9:157-160.
32. Mitch CH, Leander JD, Mendelsohn LG, Shaw WN, Wong DT, Cantrell BE, Johnson BG, Reel JK, Snoddy JD, Takemori AE, Zimmerman DM (1993) 3,4-dimethyl-4-(3-hydroxyphenyl) piperidines: opioid antagonists with potent anorectant activity. J Med Chem 36:2842-2850.
33. Moore TO, June HL, Lewis MJ (1993) Ethanol-induced stimulation and depression on measures of locomotor activity: effects of basal activity levels in rats. Alcohol 10:537-540.
34. National Advisory Council on Alcohol Abuse and Alcoholism (1988). Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation. U.S. DHHS, ADAMHA, Rockville, MD.
35. O'Malley S, Croop R, Wroblewski J, Labriola D, Volpicelli J (1995) Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatric Ann 25:11-25.
36. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49:881-887.
37. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamic-pituitary- adrenocortical axis. Psychopharmacology 160:19-29.
38. Palfai T, Davidson D, Swift R (1999) Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies. Exp Clin Psychopharmacol 7:266-273.
39. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Reviews 18:247-291.
40. Singleton EG, Tiffany ST, Henningfield JE (1999). Alcohol Craving Questionnaire (ACQ-NOW): Background, Scoring, and Administration (Revised). Intramural Research Program NIDA, Baltimore, MD.
41. Skinner HA, Alien BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91:199-209.
42. Sobell LC, Sobell MB (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption: Psychosocial and Biological Methods Alien J, Litten RZ eds), pp 41-72. Humana Press, Totowa, NJ.
43. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK (1994). Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol (Suppl) 12:70-75.
44. Sullivan JT, Naranjo CA, Sellers EM (1989a) Compliance among heavy alcohol users in clinical drug trials. J Subst Abuse 1:183-194.
45. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989b) Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment of alcohol scale (CIWA-ar). Br J Addict 84:1353-1357.
46. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151:1463-1467.
47. Thomas SE, Drobes DJ, Voronin K, Anton RF (2004) Non-treatment seeking alcoholics report greater stimulation but similar sedation from alcohol compared to social drinkers. J Stud Alcohol 65:330-335.
48. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880.
49. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 54:737-742.
50. Yan Q (1999) Extracellular dopamine and serotonin after ethanol monitored with 5-minute microdialysis. Alcohol 19:1-7.